Pharmaceutical

Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff

As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025.

Aug 15, 2024 - 04:00
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025.
Read the original article

Tags:

Previous Article

Bavarian Nordic outlays 215,000 mpox vaccine dose supply to African countries

Next Article

Diabesity: Overlapping pathophysiology informs multi-indication treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

NPX-267 by NextPoint Therapeutics for Pancreatic Ductal...

Jun 14, 2024

AstraZeneca files patent for improved production of aav...

Mar 13, 2024

STAT+: FDA delays enforcement of a pharmaceutical supply chain law to stop counterfeit drugs

STAT+: FDA delays enforcement of a pharmaceutical suppl...

Aug 29, 2023